FarmavitaR+

1. Clinical Trials 2010
(Events/Events)

... and maximizing patient recruitment, enrolment and retention • Sourcing trends in clinical trials • Trials in Central and South Eastern Europe (CEE/SEE) • How to attract and retain clinical trials ...

2. How to run the right clinical trials?
(Events/Events)

... and CROs.  Discuss with leading Pharma companies, what is the future of clinical trials & how to be prepared to succeed Key topics: • New approaches to conducting clinical trials in a current ...

3. Emerging Clinical Trial Locations
(Clinical Trilas/Europe not-EU)

... average patient recruitment rate in 2006 exceeded 4.7 patients per site per month. For some nosologies, this figure is 10 times higher than in Western Europe and the US. The Chinese CRO market was valued ...

4. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing ...

5. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... to succeed in the biosimilars sector. According to Datamonitor, the biosimilars market will grow to more than $2 billion across the seven major markets by 2014 following key patent expiries for epoetin ...

6. Drug repositioning
(Regulatory Affairs/Other issues)

... its efficacy in treating stress urinary incontinence (SUI). Following successful clinical trials, Eli Lilly succeeded in obtaining marketing approval for the drug for SUI, making it the first in class. ...

7. New Czech guideline
(eSubmissions/eSubmissions)

... compressed, incl. the root directory. For the time being it is possible to use the e-mail room only for the submission of documentation which in its compressed form does not exceed 10MB. Documentation ...

8. Czech Republic-yearly maintenance fees
(Regulatory Affairs/European Union)

... and medium-sized enterprises which defines: Small enterprise: as enterprise which employs fewer than 50 persons and whose annual turnover and/or annual balance sheet total does not exceed EUR 10 ...

9. Rx-to-OTC Strategies
(Reports/Market Report)

... enhance existing franchise revenues or protect branded revenues from generic competition. For Rx-to-OTC switches to succeed, there needs to sufficient differentiation between the existing Rx drug ...

10. Hypertension Therapy and Market Report
(Reports/Market Report)

...  Prehypertensive stage must be managed by nonpharmacological therapy. As stated above, mild hypertension can be managed by non-pharmacological therapy. It this does not succeed in 4 weeks or so, ...

11. Administrative Fees - The Czech R.
(Regulatory Affairs/European Union)

... of reference substances or expensive chemicals or kits, and the total costs of the conduct of the analysis thus exceed the amount of reimbursement stipulated in the Pricelist, the applicant shall be notified ...

12. Nanotubes Against Cancer
(Professional Articles/Life Science Article)

... graphene) rolled up into a seamless cylinder with diameter of the order of a nanometer. This results in a nanostructure where the length-to-diameter ratio exceeds 10,000. Such cylindrical carbon molecules ...

13. IMS Global Report
(Reports/Market Report)

... just five years ago,” commented Aitken. “But it is no longer enough just to be responsive. To succeed, companies need to get ahead of the dynamics that are rebalancing the market. This requires ...

14. Regulatory bodies and truth about cosmetic ingredients
(Regulatory Affairs/Regulatory Affairs News)

... Part I: Cosmetic UVFilters.International Journal of Cosmetic Science, 18, 167-177, 1996. 10. Herzog B, Sommer K. Investigations on Photostability of UV-Absorbers for Cosmetic Sunscreens. Proceedings ...

15. Business Networking
(Regulatory Affairs/Other issues)

... to making and sustaining business connections. Not long ago I spoke at an entrepreneurial conference in Wisconsin. When it was time for me to speak, the conference emcee had to practically shout into ...

16. CEE Overview
(Reports/Market Report)

... (CEE) countries. The pharmaceutical market in these countries has been relatively small when compared to the Western European countries. In 2006, the pharmaceutical market in CEE countries has been estimated ...

17. Management Practice
(QA and GMP/GMP/GLP/GCP/GDP)

... how practical a plan is in practice – a critical test of whether the BCP will succeed or fail. Stage 6 - Exercising, Maintenance & Updating: The benefits of a well thought out training and exercising ...

18. Rosiglitazone maleate
(Pharmaceutical product/Pharmaceutical product)

Avandia® Patents Afford Protection Against Generic Competition Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), ...

19. eClinical trials
(Clinical Trilas/Europe not-EU)

... cent to exceed $42bn by 2010, according to a new report by Kalorama Information, publishing division of MarketResearch.com. Global drug development spending will top $105bn (€81.5bn) by 2010 and 40 ...

20. CEE Sourcing
(Regulatory Affairs/Europe not-EU)

Central European markets to source drugs from India GIREESH CHANDRA PRASAD; TIMES NEWS NETWORK [ MONDAY, JULY 17, 2006 01:57:27 AM]   NEW DELHI: Central European countries with relatively smaller ...